SOME ASPECTS OF THE USE OF VIRUSES IN THE TREATMENT OF MALIGNANT NEOPLASMS
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-22-1-2020-g.8538Keywords:
cancer immunity, gene therapy, malignant neoplasms, oncolytic virotherapy, virusesAbstract
Aim: to analyze scientific publications dedicated to justification of the feasibility and effectiveness of viruses belonging do different taxonomic groups to be utilized in the treatment of malignant tumors (tumor biotherapy). The review describes features of the viruses which were studied as the means of oncolytic virotherapy or as the vectors in gene therapy. Virotherapy is considered to be a type of cancer patients’ treatment based on application of the viruses which selectively infect and kill cancer cells. Gene therapy implies the treatment of patients with malignant tumors with the help of viral vectors by introducing into somatic cells functioning genes which are able to repair genetic abnormalities or alter the malignant properties of a transformed cell. The mode of action, basic principles and strategy of the mentioned types of therapy are discussed. Possible limitations and complications are analyzed. The mechanisms of overcoming antitumor immune deficiency due to the utilization of therapeutic agents of viral nature are considered.
References
Kavetsky RE. The mechanisms of carcinogenesis and factors of anticarcinogenesis. Vopr Oncology 2005; 51 (6): 632–35 (in Russian).
Sitkovskaya AO, Zlatnik EYu, Novikova IA, et al. Newcastle disease virus — effective alliance in the fight against cancer. Siberian J Oncology 2019; 17 (6): 105–13 (in Russian).
Sivanandam V, LaRossa CL, Chen NG, et al. Oncolytic viruses and immune checkpoint inhibition: the best of both worlds. Mol Ther Oncolytics 2019; 25 (4): 93–106.
Wei DI, Xu JI, Chen ZNI, et al. Fighting cancer with viruses: oncolytic virus therapy in China. Hum Gene Ter 2018; 29 (2): 151–9.
Lawler SE, Speransa MC, Cho CF, et al. Oncolytic viruses in cancer treatment: a review. JAMA Oncol 2017; 3 (6): 841–49.
Nguyen T, Avci NG, Shin DH, et al. Tune up in situ autovaccination against solid tumors with oncolytic viruses. Cancers (Basel) 2018; 31 (5): 10–6.
Dock G. The influence of complicating diseases upon leukemia. Am J Med Sci 1904; 127: 563–592.
De Pace N. Sulla scomparsa di un enorme cancero vegetante del collo dell’utero senza cura chirurgica. Ginecologia 1912; 9: 82–89.
Voroshilova MK. Virological and immunological aspects of the use of ZHEV in cancer: Non-pathogenic strains of enteroviruses useful for the organism: their prophylactic and therapeutic use. M: Publishing House of the Ministry of Health of the USSR 1988: 24–9 (in Russian).
Chumakov PM, Morozova VV, Babkin IV, et al. Oncolytic enteroviruses. Molecular Biology 2012; 46: 712–725 (in Russian).
Heidbuechel JPW, Engeland CE. Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo. J Vis Exp 2019; 1: 143.
Soboleva AV, Lipatova AV, Kochetkov DV, et al. Changes in the sensitivity of glioblast cells to oncolytic enteroviruses during passaging in culture. West RSMU 2018; 2: 40–4 (in Russian).
Chumakov MP. Could Oncolytic viruses provide a break through in oncology? Vestnik-RAN 2019; 89 (5): 475–84 (in Russian).
Babiker HM, Riaz IB, Husnain M, et al. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virother 2017; 9 (6): 11–18.
Mutseniece AYa. Oncotropism of viruses and the problem of virotherapy of malignant tumors Riga: Zinatne 1972. 442 p. (in Russian).
Shetab Boushehri MA, Lamprecht A. TLR4-based immunotherapeutics in cancer: a review of the achievements and shortcomings. Mol Pharm 2018; 15 (11): 4770–800.
Vijayakumar G, Zamarin D. Design and production of newcastle disease virus for intratumoral immunomodulation. Methods Mol Biol 2020; 2058: 133–54.
Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2014; 2 (4): 295–300.
Bogoslovskaya EV, Glazkova DV, Shipulin GA, et al. Safety of Retroviral Vectors in Gene Therapy. Annals of the Russian Academy of Medical Sciences 2012; 10: 55–61 (in Russian).
Zaridze DG, ed. Kantserogenez. (Carcinogenesis.) Moscow: Meditsina 2004. 576 p. (In Russian).
Chekhun VF, ed. Oncology: Vibrancy lectures. K: Health’s 2010. 768 p. (in Ukrainian).
Ma W, He H, Wang H. Oncolytic herpes simplex virus and immunotherapy. BMC Immunol 2018; 19 (1): 40.
